Watchlist Price Alert

LeMaitre Vascular Inc. (LMAT)

NASDAQ: LMAT · Real-Time Price · USD

82.30

1.86 (2.31%)

At close: May 06, 2025, 3:59 PM

82.09

-0.26%

After-hours: May 06, 2025, 04:20 PM EDT

2.31% (1D)

Bid	78.61
Market Cap	1.86B
Revenue (ttm)	226.26M
Net Income (ttm)	45.16M
EPS (ttm)	1.93
PE Ratio (ttm)	42.64
Forward PE	32.04
Analyst	Buy

Ask	90.33
Volume	153,574
Avg. Volume (20D)	239,010
Open	80.25
Previous Close	80.44
Day's Range	79.85 - 82.86
52-Week Range	71.42 - 109.58
Beta	0.88

About LMAT

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vas...

Sector Healthcare

IPO Date Oct 19, 2006

Employees 651

Stock Exchange NASDAQ

Ticker Symbol LMAT

Website https://www.lemaitre.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for LMAT stock is "Buy." The 12-month stock price forecast is $100, which is an increase of 21.51% from the latest price.

Stock Forecasts

Earnings Surprise

LeMaitre Vascular has released their quartely earnings on May 1, 2025:

Revenue of $59.87M exceeds estimates by $2.26M, with 11.95% YoY growth.

EPS of 0.48 misses estimates by -0.02, with 9.09% YoY growth.

Why Price Moved

4 days ago

-12.79%

LeMatire Vascular shares are trading lower after t... Unlock content with Pro Subscription

3 days ago

-0.55%

LeMatire Vascular shares are trading lower after the company reported Q1 EPS guidance below estimates and lowered its FY25 EPS guidance.

News

4 days ago · seekingalpha.com

LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript

5 days ago · zacks.com

LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.

2 weeks ago · seekingalpha.com

The Elephant In The Room - March Dividend Income Report

I've sold some higher-yielding stocks and reduced my portfolio yield in March. The goal was to get closer to my core strategy of investing only in companies with low dividend yields, but high dividend...

3 weeks ago · zacks.com

LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?

LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro...

1 month ago · zacks.com

4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.

1 month ago · seekingalpha.com

Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones

Over the past decade, the iShares S&P/TSX SmallCap Index ETF has underperformed broader markets due to its heavy exposure to resource-heavy sectors like energy and materials. Acme's dividend track rec...

1 month ago · seekingalpha.com

Stocks Falling On Earnings - What To Do? February Dividend Income Report

Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contrib...

1 month ago · zacks.com

3 Reasons Growth Investors Will Love LeMaitre (LMAT)

LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes.

2 months ago · zacks.com

3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN

The Cheesecake Factory, LeMaitre Vascular and Huron Consulting Group are currently displaying superb earnings growth.

2 months ago · seekingalpha.com

When Do You Sell A Winner? - January Dividend Income Report

BlackRock is an interesting case study as I sold it for a nice profit even though the company's investment thesis is still intact. However, some metrics aren't as strong as before. I have a Telus posi...

Load More News